NasdaqGS - Nasdaq Real Time Price USD

Molecular Partners AG (MOLN)

Compare

7.23

+0.30

(+4.33%)

At close: June 28 at 4:00 PM EDT

6.94

-0.29

(-4.01%)

After hours: June 28 at 4:02 PM EDT

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Execut

GlobeNewswire 12 days ago

MLLCF

MOLN
+4.33%
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua

GlobeNewswire 15 days ago

MLLCF

MOLN
+4.33%
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profileFirst-in-human study in planning with initial data expected in 2025RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement

GlobeNewswire 18 days ago

MLLCF

MOLN
+4.33%
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamicsData support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Mo

GlobeNewswire 28 days ago

MLLCF

MOLN
+4.33%
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano Med, preclinical data to be presented at SNMMI 2024Switch-DARPin Platform: Initial data to be presented at EHA 2024; Preclinical proof-of-concept studies for c-KIT program planned for H2 2024MP0317: Final data from P

GlobeNewswire last month

MLLCF

MOLN
+4.33%
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in combination with azacitidine/venetoclaxOngo

GlobeNewswire last month

MLLCF

MOLN
+4.33%
Life Science Cares Launches in Switzerland

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communitiesZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the U

GlobeNewswire 2 months ago

MLLCF

MOLN
+4.33%
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, th

GlobeNewswire 2 months ago

MLLCF

MOLN
+4.33%
Molecular Partners Publishes Invitation to Annual General Meeting 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024. The Annual General Meeting will be held on Wednesday, April 17, 2024, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to

GlobeNewswire 3 months ago

MLLCF

MOLN
+4.33%
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activityIntroduced the Switch-DARPin concept and platform at PEGS Europe. In January 2024, introduced the first multispecific Switch-DARPin program, targeting cKIT x CD16a x CD47, as a next-generation conditioning regim

GlobeNewswire 3 months ago

MLLCF

MOLN
+4.33%
The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable

Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...

Simply Wall St. 3 months ago

MOLN
+4.33%
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners’ Chief Executive Officer Patrick Amstutz w

GlobeNewswire 3 months ago

MLLCF

MOLN
+4.33%
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline; first data on DLL3 as lead candidate; to be co-developed as 212Pb-based RDT in new partnership with Orano MedIntroduction of first program from the Switch-DARPin platform: the cKIT x CD16a x CD47 Switch-DARPin allows local conditional immu

GlobeNewswire 5 months ago

MLLCF

MOLN
+4.33%
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive payloadsCo-Development agreement covers multiple oncology targets, including DLL3Companies anticipate first-in-human studies in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),

GlobeNewswire 5 months ago

MLLCF

MOLN
+4.33%
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%

Key Insights Significant control over Molecular Partners by retail investors implies that the general public has more...

Simply Wall St. 6 months ago

MOLN
+4.33%
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during

GlobeNewswire 6 months ago

MLLCF

MOLN
+4.33%
$Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting$

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range threeMP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed Phase 1/2a trial remains ongoing with patients being enrolled in fifth of seven planned dose-escalation cohorts ZURICH-S

GlobeNewswire 6 months ago

MLLCF

MOLN
+4.33%
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com

GlobeNewswire 7 months ago

MLLCF

MOLN
+4.33%
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 7 months ago

MOLN
+4.33%
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose-escalation portion is complete, with final study results expected in H1 2024 Data support continued clinical evaluation of MP0317, including in combination studies ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE)

GlobeNewswire 7 months ago

MLLCF

MOLN
+4.33%

Performance Overview

Return	MOLN	MSCI WORLD
YTD	+72.97%	+10.81%
1-Year	+13.86%	+20.22%
3-Year	-63.81%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Molecular Partners AG (MOLN)

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

Life Science Cares Launches in Switzerland

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Performance Overview